# US 2010/0062476 A1 · Assessing mammals for vascular diseases and valvular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062476 A1
- Document ID: US20100062476A1
- Status: Published application
- Kind: A1
- Application number: 12/502,494
- Filed: 2009-07-14
- Published: 2010-03-11
- Earliest claimed: 2007-01-16
- Inventors: Sundeep Khosla; Amir Lerman; Ulrike Moedder; Mario Goessl
- Web page: https://patentgrep.com/patent/US20100062476A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/5064: {Endothelial cells}
- G01N 2333/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- G01N 2800/323: Arteriosclerosis, Stenosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This document provides methods and materials related to assessing mammals for vascular disease. This document also provides methods and materials related to assessing mammals for valvular disease. For example, methods and materials for assessing mammals for vascular disease using elevated levels of endothelial progenitor cells expressing a bone-related polypeptide (e.g., an osteocalcin polypeptide) as markers are provided.

## Claims

### Claim 1

A method of assessing a mammal suspected of having vascular disease for vascular disease, wherein said method comprises determining whether or not said mammal contains an elevated level of circulating CD34+/KDR+ endothelial progenitor cells expressing a bone-related polypeptide, classifying said mammal as having said vascular disease if said mammal contains said elevated level, and classifying said mammal as not having said vascular disease if said mammal lacks said elevated level.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein said vascular disease is early coronary atherosclerosis.

### Claim 4 (depends on 1)

The method of claim 1, wherein said vascular disease is late coronary atherosclerosis.

### Claim 5 (depends on 1)

The method of claim 1, wherein said circulating CD34+/KDR+ endothelial progenitor cells are circulating CD133+/CD34+/KDR+ endothelial progenitor cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein said circulating CD34+/KDR+ endothelial progenitor cells are circulating CD133−/CD34+/KDR+ endothelial progenitor cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein said method comprises recording that said mammal has vascular disease when said mammal contains said elevated level.

### Claim 8 (depends on 1)

The method of claim 1, wherein said method comprises recording that said mammal does not have vascular disease when said mammal lacks said elevated level.

### Claim 9

A method of assessing a mammal suspected as having valvular disease for valvular disease, wherein said method comprises determining whether or not said mammal contains an increased level of circulating CD34+/KDR+ endothelial progenitor cells expressing a bone-related polypeptide, classifying said mammal as having said valvular disease if said mammal contains said increased level, and classifying said mammal as not having said valvular disease if said mammal lacks said increased level.

### Claim 10 (depends on 9)

The method of claim 9, wherein said mammal is a human.

### Claim 11 (depends on 9)

The method of claim 9, wherein said valvular disease is aortic valve stenosis.

### Claim 12 (depends on 9)

The method of claim 9, wherein said valvular disease is severe calcific aortic valve stenosis.

### Claim 13 (depends on 9)

The method of claim 9, wherein said circulating CD34+/KDR+ endothelial progenitor cells are circulating CD133+/CD34+/KDR+ endothelial progenitor cells.

### Claim 14 (depends on 9)

The method of claim 9, wherein said circulating CD34+/KDR+ endothelial progenitor cells are circulating CD133−/CD34+/KDR+ endothelial progenitor cells.

### Claim 15 (depends on 9)

The method of claim 9, wherein said method comprises recording that said mammal has valvular disease when said mammal contains said increased level.

### Claim 16 (depends on 9)

The method of claim 9, wherein said method comprises recording that said mammal does not have valvular disease when said mammal lacks said increased level.
